Neoplasms Clinical Trials

A listing of 57 Neoplasms clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Neoplasms

1 - 12 of 57

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 57 active clinical trials seeking participants for Neoplasms research studies. The states with the highest number of trials for Neoplasms participants are California, Texas, Florida and New York.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Clinical Study

Recruiting

We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.

Conditions:

Cough

Chronic Cough

Asthma

Allergic Asthma

Sinusitis

Learn More

Featured Trial

Transcranial Magnetic Stimulation (TMS) for Obsessive Compulsive Disorder (OCD)

Recruiting

Transcranial magnetic stimulation (TMS) is an FDA-approved, non-invasive form of brain stimulation for OCD. TMS has been shown to be an effective form of treatment in individuals with OCD. By using a form of TMS termed theta-burst stimulation (TBS), we hope that this will result in a more effective treatment by producing faster symptom reduction. We are trialing a novel form of accelerated TMS, where we will deliver ten 10-minute sessions per day, for 5 days. This study will compare the efficacy of TMS for OCD at two distinct brain regions. Participants will be randomized into one of two study groups, and receive stimulation at either the DMPFC or R-OFC. Both regions have been linked to OCD by research. Patients that don't respond to their study region will have the option to receive stimulation at the other region.

Conditions:

Obsessive-Compulsive Disorder

Obsessive Compulsive Disorder

Obsessive Compulsive Disorder (OCD)

Obsessive-Compulsive Disorder (OCD)

Obsessive-compulsive Disorders and Symptoms

Learn More

Featured Trial

Type 2 Diabetes Clinical Trial

Recruiting

Can changing your breakfast improve your type 2 diabetes? Join this online study from the University of Michigan.

Conditions:

Type 2 Diabetes

Diabetes Mellitus Type 2 in Obese

Diabetes Type Two

Learn More

Addressing Cancer-Related Financial Toxicity in Rural Oncology Care Settings

NCT04931251

Recruiting

The financial burden, or financial toxicity (FT), of cancer is a consequential and growing problem, particularly for rural patients. It is important to improve our understanding of how financial navigation (FN) can reduce the material, psychological, and behavioral burden of costs associated with cancer care in both rural and non-rural community settings. The purpose of this study is to conduct a financial navigation program in 5 rural and 4 non-rural oncology practices in North Carolina and eva... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/24/2025

Locations: NC Basnight Cancer Hospital, Chapel Hill, North Carolina +8 locations

Conditions: Neoplasms, Carcinoma

Learn More ›

Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

NCT00349830

Recruiting

The purpose of this study is to measure the levels of serum proteins and other biomarkers in cancer patients and in patients suspected of having cancer. We believe that some of these markers may be useful for confirming the diagnosis or for selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/24/2025

Locations: Stanford University School of Medicine, Stanford, California

Conditions: Carcinomas (Including Squamous Cell and Adenocarcinoma), Neoplasms

Learn More ›

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

NCT03435796

Recruiting

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one GM T cell infusion will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.

Gender:

ALL

Ages:

All

Trial Updated:

01/23/2025

Locations: University of Alabama Birmingham, Birmingham, Alabama +172 locations

University of Alabama Birmingham, Birmingham, Alabama

Banner MD Anderson Cancer Center, Gilbert, Arizona

Mayo Clinic Phoenix, Phoenix, Arizona

Arizona Cancer Center, Scottsdale, Arizona

Local Institution - 01021, Tucson, Arizona

City Of Hope, Duarte, California

University Of California San Diego Moores Cancer Center, La Jolla, California

Local Institution - 01206, Los Angeles, California

Local Institution - 01043, Sacramento, California

University of California, San Francisco- California, San Francisco, California

UCLA Medical Centre-Santa Monica, Santa Monica, California

Local Institution - 01119, Stanford, California

University Of Colorado Cancer Center, Aurora, Colorado

Colorado Blood Cancer Institute, Denver, Colorado

Yale Cancer Center, New Haven, Connecticut

Local Institution - 01050, Washington, District of Columbia

The Mayo Clinic - Jacksonville, Davis-E, Jacksonville, Florida

Baptist Cancer Center, Miami, Florida

Local Institution - 01035, Orlando, Florida

H. Lee Moffitt Cancer Center and Research Institute University of South Florida, Tampa, Florida

Winship Cancer Institute of Emory University, Atlanta, Georgia

Northside Hospital, Inc, Atlanta, Georgia

Northwestern Memorial Hospital, Chicago, Illinois

University Of Chicago Medical Center, Chicago, Illinois

Local Institution - 01040, Maywood, Illinois

Local Institution - 01063, Niles, Illinois

IN Univ Simon Cancer Center, Indianapolis, Indiana

Local Institution - 01020, Indianapolis, Indiana

Kansas University Medical Center, Westwood, Kansas

Cancer Center of Kansas, Wichita, Kansas

University Of Kentucky, Lexington, Kentucky

Norton Cancer Institute Louisville Oncology, Louisville, Kentucky

Local Institution - 01026, New Orleans, Louisiana

University of Maryland - Greenebaum Comprehensive Cancer Center, Baltimore, Maryland

Sidney Kimmel Comp Cancer Center at Johns Hopkins, Baltimore, Maryland

National Cancer Institute, Bethesda, Maryland

Local Institution - 01107, Boston, Massachusetts

Massachusetts General Hospital / Dana-Farber Cancer Institute, Boston, Massachusetts

Local Institution - 01106, Boston, Massachusetts

University Of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

Karmanos Cancer Center Wayne State University, Detroit, Michigan

Providence Cancer Institute, Southfield, Michigan

M Health Fairview University of Minnesota Medical Center - East Bank, Minneapolis, Minnesota

Mayo Clinic, Rochester, Minnesota

Siteman Cancer Center, Saint Louis, Missouri

University Of Nebraska Medical Center, Omaha, Nebraska

Local Institution - 01030, East Brunswick, New Jersey

Hackensack University Medical Center, Hackensack, New Jersey

Morristown Memorial Hosp, Morristown, New Jersey

Local Institution - 01053, New Brunswick, New Jersey

New York Oncology Hematology P.C., Albany, New York

Roswell Park Cancer Institute, Buffalo, New York

Local Institution - 01066, New York, New York

Weill Cornell Medicine / New York Presbyterian Hospital, New York, New York

Icahn School Of Medicine At Mount Sinai, New York, New York

Columbia University Medical Center/New York-Presbyterian Hospital, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

Local Institution - 01051, Rochester, New York

Levine Cancer Institute, Charlotte, North Carolina

Duke University Medical Center, Durham, North Carolina

Local Institution - 01058, Salisbury, North Carolina

Oncology Hematology Care, Inc., Cincinnati, Ohio

Local Institution - 01042, Cleveland, Ohio

Cleveland Clinic Foundation, Cleveland, Ohio

University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma

Willamette Valley Cancer Institute, Eugene, Oregon

Providence Portland Medical Center, Portland, Oregon

Oregon Health and Science University OHSU, Portland, Oregon

The Children'S Hospital Of Philadelphia, Philadelphia, Pennsylvania

University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania

Thomas Jefferson University - Clinical Research Institute, Philadelphia, Pennsylvania

Fox Chase Cancer Center, Philadelphia, Pennsylvania

UPMC Cancer Pavillion, Pittsburgh, Pennsylvania

Hematology and Oncology Associates of SC, LLC, Greenville, South Carolina

Local Institution - 01064, Sioux Falls, South Dakota

Sarah Cannon Research Inst, Nashville, Tennessee

Texas Oncology, Dallas, Texas

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas

UT Southwestern Medical Center, Dallas, Texas

University of Texas- MD Anderson, Houston, Texas

Sam Clinical Research Center, San Antonio, Texas

Local Institution - 01033, Temple, Texas

Texas Oncology, P.A. - Tyler, Tyler, Texas

University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah

Intermountain Healthcare - LDS Hospital, Salt Lake City, Utah

University Of Virginia Health System, Charlottesville, Virginia

Local Institution - 01045, Norfolk, Virginia

Local Institution - 01023, Richmond, Virginia

Swedish Cancer Institute, Seattle, Washington

Local Institution - 01060, Seattle, Washington

Fred Hutchinson Cancer Center, Seattle, Washington

Local Institution - 01055, Tacoma, Washington

University Of Wisconsin, Madison, Wisconsin

Froedtert Hospital BMT Medical College of Wisconsin, Milwaukee, Wisconsin

Local Institution - 01069, Wauwatosa, Wisconsin

Allgemeinen Krankenhaus (AKH) Wien - Medizinische Universitaet Wien, Wien, Not set

Local Institution - 05200, Gent, Not set

Uz Gent, Gent, Not set

University Hospital Leuven, Leuven, Not set

Local Institution - UNK 2, Leuven, Not set

University Of Calgary, Calgary, Alberta

Local Institution - 02802, Vancouver, British Columbia

Local Institution - 02801, Hamilton, Ontario

Princess Margaret Cancer Centre, Toronto, Ontario

CIUSSS de l'Est-de-l'Ile-de-Montreal, Montreal, Quebec

Helsinki University Central Hospital (HUCH), Helsinki, Not set

CHRU de Lille France, Lille Cedex, Not set

Local Institution - 09601, Lyon, Not set

Local Institution - 09400, Marseille Cedex 9, Not set

Local Institution - 09602, Marseille Cedex 9, Not set

CHU Montpellier - Hôpital Saint Eloi, Montpellier CEDEX 5, Not set

Chu Hotel Dieu, Nantes Cedex 01, Not set

Hopital Saint Louis, Paris, Not set

Hospital Saint Louis, Paris, Not set

Local Institution - 09600, Paris, Not set

Centre Hospitalier Lyon-Sud, Pierre-Benite CEDEX, Not set

CHU La Miletrie, Poitiers Cedex, Not set

Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse CEDEX 9, Not set

Gustave Roussy, Villejuif, Not set

Robert-Rossle-Klinik im HELIOS Klinikum Berlin-Buch Klinik fur Hamatologie, Onkologie u. Tumorimmuno, Berlin, Not set

Local Institution - 03155, Berlin, Not set

Universitatsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Not set

Local Institution - 03513, Dusseldorf, Not set

Local Institution - 03500, Frankfurt, Not set

Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Not set

Universitatsklinikum Heidelberg, Heidelberg, Not set

Kinikum der Universitaeat zu Koeln, Koeln, Not set

Local Institution - 03454, Muenster, Not set

LMU Klinikum der Universität, München, Not set

Local Institution - 03503, Tuebingen, Not set

University Hospital of Ulm, Ulm, Not set

Universitatsklinikum Wurzburg Medizinische Klinik und Poliklinik II, Würzburg, Not set

Ospedali Riuniti di Ancona, Ancona, Not set

Azienda Ospedaliero Universitaria Di Bologna Policlinico Sorsola Malpighi, Bologna, Not set

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Not set

Fondazione Monza e Brianza per il Bambino e la sua Mamma (MBBM), Monza, Not set

Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale, Naples, Not set

Local Institution - 07500, Roma, Not set

Ospedale Pediatrico Bambino Gesu, Rome, Not set

Istituto Clinico Humanitas, Rozzano (MI), Not set

Local Institution - 07610, Torino, Not set

Azienda Sanitaria Ospedaliera San Giovanni Battista Molinette, Turin, Not set

Hokkaido University Hospital, Sapporo-shi, Hokkaido

National Cancer Center Hospital, Chuo-ku, Tokyo

Toranomon Hospital, Minato-ku, Tokyo

Local Institution - 13202, Bunkyo-ku, Not set

Kyushu University Hospital, Fukuoka, Not set

Tokai University Hospital, Isehara City, Kanagawa, Not set

Nagoya City University Hospital, Nagoya, Not set

Osaka Metropolitan university Hospital, Osaka, Not set

Japan Red Cross Medical Center, Shibuya-ku, Not set

Jichi Medical University Hospital, Shimotsuke, Not set

Local Institution - 13804, Shinjuku City, Not set

Local Institution - 04650, Amsterdam, Not set

Erasmus Medical Center - Daniel den Hoed, Rotterdam, Not set

Local Institution - 04400, Utrecht, Not set

Oslo Universitetssykehus, Oslo, Not set

Hospital Universitario Vall D hebron, Barcelona, Not set

Hospital Universitari Germans Trias i Pujol ICO Badalona, Barcelona, Not set

Institut Clinic de Nefrologia i Urologia - Hospital Clinic i Provincial de Barcelona, Barcelona, Not set

Hospital San Joan de Deu Barcelona, Esplugues de Llobregat, Not set

Hospital Infantil Universitario Nino Jesus, Madrid, Not set

Hospital 12 De Octubre, Madrid, Not set

Clinica Universidad de Navarra, Pamplona, Not set

Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca, Salamanca, Not set

Hospital Virgen Del Rocio, Sevilla, Not set

Karolinska University Hospital Huddinge, Stockholm, Not set

Inselspital Bern, Bern, Not set

Local Institution - 10850, Leeds, Not set

Kings College Hospital, London, Not set

UCL Cancer Institute, London, Not set

Christie Hospital Nhs Trust, Manchester Withington, Not set

Somers Cancer Research Building, Shirley Southampton, Not set

Conditions: Neoplasms

Learn More ›

Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members

NCT00071045

Recruiting

This study will collect biological samples for use in research experiments aimed at better understanding the clinical features of certain diseases. The specimens may be used to evaluate the effectiveness of known therapies, refine treatment approaches, identify potential new therapies, and explore opportunities for disease prevention. The following individuals 2 years of age or older may be eligible for this study: * Patients with a cancerous solid tumor or a cancerous or non-cancerous blood disorder who are being screened for or who are enrolled in a treatment study at the NIH Clinical Center * HLA-compatible donor family members (18 years of age or older) of the above patients who are being evaluated for or are enrolled in an NIH study as a stem cell transplant donor * Patients with a cancerous solid tumor or a cancerous or non-cancerous blood disorder or a bone marrow failure condition who cannot participate in an NIH treatment protocol or travel to the NIH Clinical Center and who are referred for participation through their home health care provider. Research samples will be collected from participants when blood is drawn or bone marrow, urine, or stool is collected, or tumor or other tissue is biopsied as part of their general medical care. Investigators may periodically request an additional sample of blood, stool, or urine. Participants who are 18 years of age or older may donate a large number of white blood cells through a procedure called leukapheresis. This procedure is not part of general medical care and would be done for research purposes only. For apheresis, a catheter (plastic tube) is placed in a vein in the subject's arm. Blood flows from the vein into a cell separator machine, where the white cells are separated from the red cells, platelets, and plasma by a spinning process. The white cells are removed and collected, and the rest of the blood is returned to the subject through a second tube placed in the other arm. Read Less

Gender:

ALL

Ages:

Between 2 years and 100 years

Trial Updated:

01/18/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Neoplasms, Hematologic Neoplasms, Healthy Volunteers

Learn More ›

5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

NCT03366116

Recruiting

Background: Blood, tissue, and tumor cells contain genes. Genes are made up of DNA. DNA is the instruction book for each cell. In some people with cancer, the genes that might have slowed the growth of their tumor were turned off. Researchers want to see if a new drug can turn the genes back on and slow the tumor growth. The drug is called Aza-TdC. Objective: To test the safety of Aza-TdC, and to find out the dose of this drug that can be safely given to humans. Eligibility: People ages 18... Read More

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

01/18/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Neoplasms, Solid Tumors

Learn More ›

HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma

NCT04482933

Recruiting

This study is a clinical trial to assess the efficacy and confirm the safety of intratumoral inoculation of G207 (an experimental virus therapy) combined with a single 5 Gy dose of radiation in recurrent/progressive pediatric high-grade gliomas

Gender:

ALL

Ages:

Between 3 years and 21 years

Trial Updated:

01/17/2025

Locations: Memorial Sloan Kettering, New York, New York +2 locations

Conditions: Neoplasms, High Grade Glioma, Glioblastoma Multiforme, Malignant Glioma of Brain, Anaplastic Astrocytoma of Brain, High-grade Glioma, Anaplastic Glioma, Giant Cell Glioblastoma

Learn More ›

Development of a Culturally Tailored Resilience-building Intervention for Chinese American's Advance Care Planning Discussions

NCT06247215

Recruiting

Less than 15% of Chinese Americans complete advance directives. That is less than half of the 37% completion rate in the US general population. This disparity in the use of advance care planning between White Americans and Chinese Americans may extend to disparities in end-of-life care. To address such disparities in end-of-life care, we will develop and assess the acceptability of a culturally tailored resilience-building intervention to help Chinese Americans with cancer or heart disease and t... Read More

Gender:

ALL

Ages:

Between 18 years and 80 years

Trial Updated:

01/17/2025

Locations: University of Illinois Chicago, Chicago, Illinois

Conditions: Advance Care Planning, Neoplasms, Heart Diseases

Learn More ›

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

NCT03602157

Recruiting

The body has different ways of fighting infection and disease. No single way is perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are proteins that protect the body from disease caused by bacteria or toxic substances. Antibodies work by binding bacteria or substances, which stops them from growing and causing bad effects. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected with bacteria or viruses. Both antibodies and T cells have been used to treat patients with cancers. They both have shown promise, but neither alone has been sufficient to treat cancer. This study will combine both T cells and antibodies in order to create a more effective treatment called Autologous T Lymphocyte Chimeric Antigen Receptor cells targeted against the CD30 antigen (ATLCAR.CD30). Another treatment being tested includes the Autologous T Lymphocyte Chimeric Antigen Receptor cells targeted against the CD30 antigen with CCR4 (ATLCAR.CD30.CCR4) to help the cells move to regions in the patient's body where the cancer is present. Participants in this study will receive either ATLCAR.CD30.CCR4 cells alone or will receive ATLCAR.CD30.CCR4 cells combined with ATLCAR.CD30 cells. Previous studies have shown that a new gene can be put into T cells that will increase their ability to recognize and kill cancer cells. The new gene that is put in the T cells in this study makes an antibody called anti-CD30. This antibody sticks to lymphoma cells because of a substance on the outside of the cells called CD30. Anti-CD30 antibodies have been used to treat people with lymphoma but have not been strong enough to cure most patients. For this study, the anti-CD30 antibody has been changed so instead of floating free in the blood it is now joined to the T cells. When an antibody is joined to a T cell in this way it is called a chimeric receptor. These CD30 chimeric (combination) receptor-activated T cells (ATLCAR.CD30) can kill some of the tumor, but they do not last very long in the body and so their chances of fighting the cancer are unknown. Researchers are working to identify ways to improve the ability of ATLCAR.CD30 to destroy tumor cells. T cells naturally produce a protein called CCR4 which functions as a navigation system directing T cells toward tumor cells specifically. In this study, researchers will also genetically modify ATLCAR.CD30 cells to produce more CCR4 proteins and they will be called ATLCAR.CD30.CCR4. The study team believes that the ATLCAR.CD30.CCR4 cells will be guided directly toward the tumor cells based on their navigation system. In addition, the study team believes the majority of ATLCAR.CD30 cells will also be guided directly toward tumor cells when given together with ATLCAR.CD30.CCR4, increasing their anti-cancer fighting ability. This is the first time ATLCAR\>CD30.CCR4 cells or combination of ATLCAR.CD30.CCR4 and ATLCAR.CD30 cells are used to treat lymphoma. The purpose of this study to determine the following: * What is the safe dose of ATLCAR.CD30.CCR4 cells to give to patients * What is the safe dose of the combination of ATLCAR.CD30 and ATLCAR.CD30.CCR4 cells to give to patients Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/15/2025

Locations: Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina

Conditions: Lymphoma, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Cutaneous Lymphoma, Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphomatoid Papulosis, Cutaneous T Cell Lymphoma, Gray Zone Lymphoma

Learn More ›

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

NCT05797246

Recruiting

Background: Recurrent respiratory papillomatosis (RRP) is a rare disease that causes wart-like growths in the airways. These growths come back when removed; some people may need 2 or more surgeries per year to keep their airways clear. Better treatments are needed. Objective: To see if a drug called bevacizumab can reduce the number of surgeries needed in people with RRP. Eligibility: People aged 18 and older with recurrent RRP; they must need surgery to remove the growths in their airways.... Read More

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

01/14/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Respiratory Tract Diseases, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Neoplasms, Squamous Cell, Tumor Virus Infections, Infections, Virus Diseases, DNA Virus Infections, Pathologic Processes, Disease Attributes, Recurrence, Papilloma, Respiratory Tract Infections, Papillomavirus Infections

Learn More ›

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

NCT04008797

Recruiting

The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s), and to determine the optimal dose of E7386 in combination with lenvatinib in endometrial carcinoma (EC) (for EC Dose Optimization Part only).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/09/2025

Locations: University of California San Diego (UCSD) - Moores Cancer Center(All), La Jolla, California +72 locations

University of California San Diego (UCSD) - Moores Cancer Center(All), La Jolla, California

Cedars-Sinai Medical Center, Los Angeles, California

Pasadena Liver Center, Pasadena, California

UCLA University of California - Los Angeles, Santa Monica, California

University of Colorado Cancer Center - Anschutz Medical Campus, Aurora, Colorado

Florida Cancer Specialists - South, Sarasota, Florida

Florida Cancer Specialists - East, West Palm Beach, Florida

Kansas City Research Institute, Kansas City, Missouri

Perlmutter Cancer Center- NYU Langone Health, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

University of Oklahoma Health Science Center, Oklahoma City, Oklahoma

Medical University of South Carolina, Charleston, South Carolina

Vanderbilt University Medical Center (VUMC) - Vanderbilt-Ingram Cancer Center (VICC) - Nashville, Nashville, Tennessee

Mary Crowley Cancer Research, Dallas, Texas

University of Texas Southwestern Medical, Dallas, Texas

MD Anderson Cancer Center, Houston, Texas

Beijing Cancer Hospital, Beijing, Not set

Peking Union Medical College Hospital, Beijing, Not set

Bethune Hospital of Jilin University, Changchun, Not set

Fujian Provincial Cancer Hospital, Fuzhou, Not set

Sun Yan-sen University Cancer Center, Guangzhou, Not set

Sun Yat-Sen Memrial Hospital, Sun Yat-Sen University, Guangzhou, Not set

Cancer Hospital of Shandong First Medical University, Jinan, Not set

Yunnan Cancer Hospital, Kunming, Not set

Fudan University Cancer Center, Shanghai, Not set

The Tenth People's Hospital; Shanghai Tongji University, Shanghai, Not set

Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, Not set

Tianjin Cancer Hospital, Tianjin, Not set

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Not set

CHU Amiens-Picardie (Hopital Sud), Amiens, Not set

Centre François Baclesse, Caen, Not set

Centre Jean Perrin, Clermont-Ferrand, Not set

Hôpital Beaujon, Clichy, Not set

Centre Georges-François Leclerc, Dijon, Not set

Grenoble University Hospital (Centre Hospitalier Universitaire Grenoble Alpes), La Tronche, Not set

CHU de LILLE - Hôpital HURIEZ, Lille, Not set

Hepatology, Hopital de la Croix-Rousse - 103 grande rue de la Croix-Rousse, Lyon, Not set

Centre Léon Bérard, Lyon, Not set

Institut Paoli-Calmettes, Marseille, Not set

Centre Antoine Lacassagne, Nice, Not set

Institut Curie - Centre de Recherche, Paris, Not set

APHP Hospital Saint-Antoine, Paris, Not set

AP-HP Université de Paris, Port Royal, Paris, Not set

Hopital Europeen Georges-Pompidou (HEGP), Paris, Not set

Hopital de la Croix Saint-Simon, Paris, Not set

Centre Hospitalier Universitaire de Bordeaux (CHU Bordeaux)(Hopitaux de Bordeaux) - Groupe hospitalier Sud - Hopital Haut-Levequ, Pessac, Not set

Centre Hospitalier Universitaire (CHU) de Poitiers, Poitiers, Not set

Insitute de Cancérologie de l'Ouest - Centre René Gauducheau, Saint-Herblain, Not set

ICANs, Strasbourg, Not set

Gustave Roussy Institute (IGR), Villejuif, Not set

Eisai Trial Site #5, Nagoya, Aichi

Eisai Trial Site #11, Toyoake, Aichi

Eisai Trial Site #2, Kashiwa, Chiba

Eisai Trial Site #8, Matsuyama, Ehime

Eisai Trial Site #7, Kurume, Fukuoka

Eisai Trial Site #10, Kawasaki, Kanagawa

Eisai Trial Site #12, Kamigyo-ku, Kyoto

Eisai Trial Site #3, Osakasayama, Osaka

Eisai Trial Site #9, Hidaka, Saitama

Eisai Trial Site #1, Chuo-Ku, Tokyo

Eisai Trial Site #6, Koto-ku, Tokyo

Eisai Trial Site #4, Chiba, Not set

Eisai Trial Site #1, Seongnamsi Bundang, Gyeonggi-Do

Eisai Trial Site #5, Jongno-gu, Seoul

Eisai Trial Site #2, Seodaemun, Seoul

Eisai Trial Site #4, Songpa-gu, Seoul

Eisai Trial Site #3, Seoul, Not set

Chang Gung Medical Foundation - Kaohsiung Branch, Kao-Hsiung, Not set

Taichung Veterans General Hospital, Taichung, Not set

National Cheng Kung University Hospital, Tainan, Not set

National Taiwan University Hospital, Taipei, Not set

Taipei Veterans General Hospital, Taipei, Not set

Chang Gung Medical Foundation - Linkou Branch, Taoyuan, Not set

Conditions: Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Learn More ›

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

NCT06150157

Recruiting

The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D\[s\]) and optimal dosing schedule(s) of JNJ-88549968, in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s), in part 2 (Cohort Expansion).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/09/2025

Locations: City of Hope, Duarte, California +18 locations

Conditions: Myeloproliferative Disorders, Essential Thrombocythemia, Neoplasms, Myelofibrosis

Learn More ›

Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors

NCT02211755

Recruiting

Background: - Researchers want to develop better ways to treat cancer. In this study, they will give people with cancer two drugs. These drugs have been used on their own to treat some blood cell cancers. Objectives: - To test the safety and efficacy of the drug combination of bortezomib and clofarabine. Eligibility: - Adults age 18 and over with advanced cancer that has progressed after receiving standard treatment or that has no effective therapy. Design: * Participants will be screened... Read More

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

01/07/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Neoplasms, Myelodysplastic Syndromes, Lymphomas

Learn More ›

1 - 12 of 57